ArticleHeart international
Ranolazine preserves and improves left ventricular ejection fraction and autonomic measures when added to guideline-driven therapy in chronic heart failure.
Article in Heart international. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Ranolazine as an adjunct to standard therapy for angina in myocardial bridging: a randomized clinical trial.Scientific reports · 2026Trial
- Doxorubicin-Induced Cardiac Remodeling: Mechanisms and Mitigation Strategies.Cardiovascular drugs and therapy · 2026Review
- Riluzole is associated with reduced risk of heart failure.European journal of neurology · 2025Article
- Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice.Biomedicines · 2023Review
- Driving force of deteriorated cellular environment in heart failure: Metabolic remodeling.Clinics (Sao Paulo, Brazil) · 2023Review
- Autonomic Testing Optimizes Therapy for Heart Failure and Related Cardiovascular Disorders.Current cardiology reports · 2022Review
- Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Sudden Cardiac Death in the General Population: Can We Improve Risk Stratification and Prevention?The International journal of angiology : official publication of the International College of Angiology, Inc · 2021Article
- Choice of Tactics for Experimental Therapy of Chronic Heart Failure with ALM-802 Compound.Bulletin of experimental biology and medicine · 2021Article
- Treatment of Heart Failure with Mid-Range Ejection Fraction: What Is the Evidence.Journal of clinical medicine · 2021Review
- Recently Approved and Under Investigation Drugs for Treating Patients with Heart Failure.Current cardiology reviews · 2020Review
- Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant NaJournal of cellular physiology · 2019Article
- Heart Failure Differentially Modulates Natural (Sinoatrial Node) and Ectopic (Pulmonary Veins) Pacemakers: Mechanism and Therapeutic Implication for Atrial Fibrillation.International journal of molecular sciences · 2019Review
- Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?Sultan Qaboos University medical journal · 2018Review
- Left ventricular ejection fraction as therapeutic target: is it the ideal marker?Heart failure reviews · 2017Review
- Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure.Diseases (Basel, Switzerland) · 2017Review
- Adult Human Primary Cardiomyocyte-Based Model for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-arrhythmia Risk.Frontiers in physiology · 2017Article
- Metabolic Therapy in Heart Failure.Cardiac failure review · 2015Article
- Ranolazine: Multifaceted Role beyond Coronary Artery Disease, a Recent Perspective.Heart views : the official journal of the Gulf Heart AssociationReview
- Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.Indian heart journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRanolazine (RAN) reduces cardiac sodium channel 1.5's late sodium current in congestive heart failure (CHF), reducing myocardial calcium overload, potentially improving left ventricular (LV) function. RAN blocks neuronal sodium channel 1.7, potentially altering parasympathetic and sympathetic (P&S) activity. The effects of RAN on LV ejection fraction (LVEF) and P&S function in CHF were studied.
methodsMatched CHF patients were given open-label RAN (1000 mg po-bid) added to guideline-driven therapy (RANCHF, 41 systolic, 13 diastolic) or no adjuvant therapy (control, NORANCHF, 43 systolic, 12 diastolic). Echocardiographic LVEF and P&S measures were obtained at baseline and follow-up (mean 23.7 months).
resultsLVEF increased in 70% of RANCHF patients, an average of 11.3 units. Mean LVEF remained unchanged in NORANCHF patients. P&S measures indicated cardiovascular autonomic neuropathy (P≤0.1 bpm(2)) in 20% of NORANCHF patients at baseline and in 29% at follow-up (increasing in both groups). At baseline, 28% of patients had high sympathovagal balance (SB), RAN normalized SB over 50% of these; in contrast, the NORANCHF group had a 20% increase in patients with high SB.
conclusionsRAN preserves or improves LVEF and decreases high SB in CHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.